Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month
Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026
Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program
Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial
